Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:gup.ub.gu.se/298400" > Dissection of synap...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Tible, M. (author)

Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

Article/chapterEnglish2020

Publisher, publication year, extent ...

2020-06-25
Ovid Technologies (Wolters Kluwer Health),2020

Numbers

LIBRIS-ID:oai:gup.ub.gu.se/298400
https://gup.ub.gu.se/publication/298400URI
https://doi.org/10.1212/wnl.0000000000010131DOI

Supplementary language notes

Language:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Objective To assess the ability of a combination of synaptic CSF biomarkers to separate Alzheimer disease (AD) and non-AD disorders and to help in the differential diagnosis between neurocognitive diseases. Methods This was a retrospective cross-sectional monocentric study. All participants explored with CSF assessments for neurocognitive decline were invited to participate. After complete clinical and imaging evaluations, 243 patients were included. CSF synaptic (GAP-43, neurogranin, SNAP-25 total, SNAP-25aa40, synaptotagmin-1) and AD biomarkers were blindly quantified with ELISA or mass spectrometry. Statistical analysis compared CSF levels between the various groups of AD dementias (n = 81), mild cognitive impairment (MCI)-AD (n = 30), other MCI (n = 49), other dementias (OD) (n = 49), and neurologic controls (n = 35) and their discriminatory powers. Results All synaptic biomarkers were significantly increased in patients with MCI-AD and AD-dementia compared to the other groups. All synaptic biomarkers could efficiently discriminate AD dementias from OD (AUC >= 0.80). All but synaptotagmin were also able to discriminate patients with MCI-AD from controls (area under the curve [AUC] >= 0.85) and those with AD dementias from controls (AUC >= 0.80). Overall, CSF SNAP-25aa40 had the highest discriminative power (AUC 0.93 between patients with AD dementias and controls or OD, AUC 0.90 between those with MCI-AD and controls). Higher levels were associated with 2 alleles ofAPOE epsilon 4. Conclusion All synaptic biomarkers tested had a good discriminatory power to distinguish patients with AD abnormal CSF from those with non-AD disorders. SNAP25aa40 demonstrated the highest power to discriminate AD CSF-positive patients from patients without AD and neurologic controls in this cohort. Classification of evidence This retrospective study provides Class II evidence that CSF synaptic biomarkers discriminate patients with AD from those without AD.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Neurovetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Neurosciences hsv//eng
cerebrospinal-fluid biomarker
mild cognitive impairment
association
workgroups
diagnostic guidelines
protein neurogranin
national
institute
dementia
tau
gap-43
recommendations
Neurosciences & Neurology

Added entries (persons, corporate bodies, meetings, titles ...)

Sandelius, ÅsaGothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi,Institute of Neuroscience and Physiology, Department of Physiology (author)
Höglund, Kina,1976Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xgukri (author)
Brinkmalm, AnnGothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xbrian (author)
Cognat, E. (author)
Dumurgier, J. (author)
Zetterberg, Henrik,1973Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xzethe (author)
Hugon, J. (author)
Paquet, C. (author)
Blennow, Kaj,1958Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xbleka (author)
Göteborgs universitetInstitutionen för neurovetenskap och fysiologi, sektionen för fysiologi (creator_code:org_t)

Related titles

In:Neurology: Ovid Technologies (Wolters Kluwer Health)95:80028-38781526-632X

Internet link

Find in a library

Neurology (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Tible, M.; Sandelius, Åsa; Höglund, Kina, 1 ...; Brinkmalm, Ann; Cognat, E.; Dumurgier, J.; show more...; Zetterberg, Henr ...; Hugon, J.; Paquet, C.; Blennow, Kaj, 19 ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Neurosciences

Articles in the publication: Neurology

By the university: University of Gothenburg

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se